Shares of Biogen (BIIB) are down about 1% near 8 am ET, off their earlier session lows, after competitor Eli Lilly’s (LLY) TRAILBLAZER-ALZ 2 Phase 3 study showed that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Shares of Eli Lilly are up $24.30, or 6%, to $428.50 in pre-market trading following the report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB: